Ross Osborn
Stock Analyst at Cantor Fitzgerald
(2.06)
# 2,865
Out of 5,182 analysts
112
Total ratings
32.38%
Success rate
-1.55%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $7.65 | +69.93% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $19.62 | +63.10% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $2.39 | +276.57% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $114.52 | -17.05% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $13.15 | +90.11% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $3.34 | +259.28% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $10.01 | +19.88% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $2.74 | +155.47% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.06 | +88.68% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $17.25 | -1.45% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $1.86 | +383.87% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $18.93 | +143.00% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $1.02 | +684.31% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $39.39 | -39.07% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.98 | +102.02% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $5.66 | +59.01% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $4.56 | +360.53% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $3.00 | +433.33% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.59 | +120.13% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.14 | +1,735.54% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $258 | $8.40 | +2,975.00% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $7.65
Upside: +69.93%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $19.62
Upside: +63.10%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $2.39
Upside: +276.57%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $114.52
Upside: -17.05%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $13.15
Upside: +90.11%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $3.34
Upside: +259.28%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $10.01
Upside: +19.88%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $2.74
Upside: +155.47%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.06
Upside: +88.68%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $17.25
Upside: -1.45%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $1.86
Upside: +383.87%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $18.93
Upside: +143.00%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.02
Upside: +684.31%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $39.39
Upside: -39.07%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.98
Upside: +102.02%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $5.66
Upside: +59.01%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $4.56
Upside: +360.53%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $3.00
Upside: +433.33%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.59
Upside: +120.13%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.14
Upside: +1,735.54%
Aug 18, 2023
Reiterates: Neutral
Price Target: $258
Current: $8.40
Upside: +2,975.00%